Are you testing for Ki67 expression levels in patients with early-stage hormone receptor-positive/HER2-negative breast cancer? Read this commentary for a pathologist’s perspective on Ki67 testing.
Sunil Badve, MD, FRCPath
Format: Adobe Acrobat (.pdf)
File Size: 316 KB
Released: December 28, 2021
Acknowledgements
Provided by a partnership between the American Society for Clinical Pathology and Clinical Care Options, LLC.